The University of Colorado Cancer Center proposes to establish a Specialized Program in Research Excellence (SPORE) in Lung cancer to expand our understanding of the biology of lung cancer, to find new methods of diagnosis, prevention and treatment and to serve as a regional, national and international resource for the study of lung cancer. As a part of this SPORE application we will conduct interrelating research projects, 8 clinical trials and support the 5 cores, the career development of 4 young investigators and the recruitment of new investigators with special research capabilities. Our research studies will focus on abnormalities in growth factors pathways, changes in preneoplastic epithelium, and abnormalities in lung cancer cells. This will include the study of oncogenes and suppressor genes and methods to reverse abnormalities. We will define intermediate markers associated with premalignant lesions and whether these markers change in response to discontinuation of smoking, retinoic acid therapy or other chemopreventive measures. We will study agents which interfere with lung cancer signal transduction and determine whether these are safe and useful for the treatment or prevention of lung cancer. We will assess strategies to stop cigarette consumption with high risk patients and the effects this has on intermediate markers. We will establish new clinical protocols and conduct them alone or in collaboration with other institutions. We will establish two """"""""Banks"""""""" of tissues: 1) a premalignant bank to include sputum and bronchial biopsies, bronchial brushings, bronchial lavage and urine; 2) a malignant bank to include tumor tissue, adjacent lung serum, and lymphocytes. These tissues will be studied by our investigators and made available to the scientific community on a peer-reviewed/availability basis. We will collaborate with other lung cancer SPORES and lung cancer investigators to reach our goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-03
Application #
2098886
Study Section
Special Emphasis Panel (SRC (52))
Project Start
1992-09-30
Project End
1996-08-31
Budget Start
1994-09-01
Budget End
1996-08-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105

Showing the most recent 10 out of 435 publications